Skip to main content

Advertisement

Table 2 Smoking abstinence by group

From: Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation

Group Continuous abstinencea Seven-day point-prevalence abstinence
  Abstainers (%) Crude OR (95% CI) ORb(95% CI) Abstainers (%) Crude OR (95% CI) ORb(95% CI)
Week 8       
Varenicline + nicotine patch (N = 170) 72 (42.2%) 1.08 (0.7 to 1.7) 1.04 (0.4 to 2.1) 80 (47.2%) 1.06 (0.7 to 1.6) 1.02 (0.3 to 1.6)
Varenicline + placebo (N = 171) 69 (40.4%) 1 1 78 (45.7%) 1 1
Week 12       
Varenicline + nicotine patch (N = 170) 66 (39.1%) 1.37 (0.8 to 21.) 1.24 (0.8 to 2.6) 68 (40.2%) 1.37 (0.8 to 2.1) 1.20 (0.7 to 2.1)
Varenicline + placebo (N = 171) 54 (31.8%) 1 1 56 (38.5%) 1 1
Week 24       
Varenicline + nicotine patch (N = 170) 56 (32.8%) 1.25 (0.8 to 2.0) 1.17 (0.4 to 1.9) 60 (35.1%) 1.28 (0.8 to 2.0) 1.15 (0.4 to 2.0)
Varenicline + placebo (N = 171) 48 (28.2%) 1 1 51 (33.4%) 1 1
  1. aContinuous abstinence from weeks 2 to 8, 12 and 24 weeks; badjusted by age, gender and therapist. CI, confidence interval; N, number; OR, odds ratio.